Gene clues could personalize cetuximab treatment for head and neck cancer
NCT ID NCT01827956
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study examined whether certain gene variations (FCGR2A and FCGR3A) influence how well the drug cetuximab works in people with advanced upper aerodigestive tract cancers that have spread or come back. Researchers analyzed blood samples from 121 participants to look for these genetic markers. The goal was to find a way to predict which patients are more likely to benefit from cetuximab, potentially allowing for more personalized treatment decisions in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cetuximab
- What this could lead to
- If successful, this could help doctors predict which patients will benefit most from cetuximab, leading to more personalized treatment.
- What could go wrong
- This is a small, completed observational study that only looks at genetic markers. It does not test a new treatment, so it may not directly change patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE UPPER AERODIGESTIVE TRACT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Bergonié
Bordeaux, Aquitaine, 33000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.